

The founders of Melior Capital Management (MCM) announce the incorporation of MCM in Zug (Switzerland) to provide funding for life science companies based in the USA, EU, Asia and the Middle-East.

Melior assists emerging companies in this sector to accomplish their goals, while addressing a growing demand from investors to access pre-IPO opportunities in the life science sector on a company level rather than through funds. Melior does not manage a fund.

Melior is being launched by an experienced group of individuals who understand the real opportunity of a fresh approach to financing within the life science sector. The approach brings together a renowned, world-class team of experts from the sector to minimise commercial risks through due diligence and consideration of the interests of each stakeholder.

Melior's team has a proven track record of over 70 drugs and devices taken to market during their careers, including a number of multi-billion-dollar blockbusters. The founding members of Melior synergistically combines the expertise of scientists and professionals with business credentials.

Dr Philip Lavin brings an extensive life sciences background in getting to commercial successes for separate statin and silicate blockbuster drugs, many orthopaedic devices, as well as multiple widely used screening and diagnostic tests. Dr Lavin is the first person to be an elected fellow of ASA and RAPS. He has specialized in this sector for over 40 years. He holds a PhD from Brown University and was a professor at the Harvard School of Public Health and Harvard Medical School for over 25 years.

Mickael Marsali brings all facets of fundraising, management and operational support inclusive of personnel, contracts, due diligence, sales, team building and developing marketing strategies. He brings 25 years of continuous experience in corporate & structured finance, wealth management and private equity.

Melior's clients will have access to a well-researched, diversified, and compelling portfolio of life science projects from which they can invest in the companies that they choose. The current investee pipeline includes:

- A medical device company that has just received the FDA clearance for a cost-effective, robotically controlled low-energy laser reducing abdominal fat, which partnered with Melior to test extended uses;



- A medical device company that has a new, less invasive device to treat mitral regurgitation without the need of conducting major surgeries. The device is currently being tested in animals and if successful, will be tested in humans within two years;
- A drug company that has a new drug to be combined with an existing drug administered in advance to prevent acute kidney injury following open heart surgery. Three Phase 1-2 studies are underway with a Phase 2-3 study being planned.

Melior is continuously expanding its investee pipeline with additional innovative and vetted projects, and welcomes the opportunity to work with regulated intermediaries, such as wealth managers, private banks, single and multi-family offices and other professional advisers who represent both private and institutional investors globally.

MCM seeks the best in class paradigm-shifting companies in this sector.

Melior Capital Management

AG Baarerstrasse 25,
6300 Zug,
Switzerland

e: info@meliorcm.com

w: www.meliorcm.com